Jamie E Chaft
ECOG-ACRIN Cancer Research Group · Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jamie E Chaft as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:43 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT02595944 · Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)National Cancer Institute (NCI) · active not recruiting · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7 · principal investigator
- Ph1NCT01836341 · Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive ChemoradiationMemorial Sloan Kettering Cancer Center · withdrawn · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT01443078 · Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)Memorial Sloan Kettering Cancer Center · completed · Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:43 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Prognostic value of tumor hypoxia, as measured by 18F-FMISO Breath Hold PET/CTU01CA157442 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2013 to 2014 · $486,303 awarded in 2014Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT02595944
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:43 UTC. The ranking covers the 200 most relevant of 30 PubMed records, and a shared surname and initials can bring in a namesake. All 30 on PubMed
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.N Engl J Med · 20181,689 citationsRCR 52.2
- Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.N Engl J Med · 20231,104 citationsRCR 94.7
- Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.Ann Oncol · 2017538 citationsRCR 16.9
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.Lancet Oncol · 2016525 citationsRCR 15.3
- 499 citationsRCR 13.9
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).J Clin Oncol · 2017335 citationsRCR 9.4
- 320 citationsRCR 34.5
- Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.Nat Med · 2022245 citationsRCR 14.0
- SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.J Clin Oncol · 2019188 citationsRCR 6.8
- Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.Future Oncol · 2021183 citationsRCR 9.7